Skip to main content
. 2023 Mar 28;12:e83694. doi: 10.7554/eLife.83694

Table 3. Baseline characteristics of the fourth dose cohort.

N (%)
Baseline seronegative 7 (39%)
Baseline low positive (spike ab <1000 AU/mL) 11 (61%)
Cancer diagnosis
CLL 7 (39%)
Waldenstrom’s macroglobulinemia 3 (17%)
DLBCL 2 (11%)
Multiple myeloma 2 (11%)
Mantle cell Lymphoma 1 (6%)
Marginal zone lymphoma 1 (6%)
Hodgkins lymphoma 1 (6%)
MDS 1 (6%)
Fourth dose vaccine type
BNT162b2 15 (83%)
Ad26.CoV2.S 3 (17%)